

Commentary

Impact of Fungi on Immune Responses

Pio Conti, PhD¹; Lucia Tettamanti, PhD²; Filiberto Mastrangelo, PhD³; Gianpaolo Ronconi, PhD⁴; Ilias Frydas, PhD⁵; Spiros K. Kritas, PhD⁶; Alessandro Caraffa, MD⁷; and Franco Pandolfi⁸

¹Immunology Division, Postgraduate Medical School, University of Chieti-Pescara, Chieti, Italy;

²Department of Medical and Morphological Science, University of Insubria, Varese, Italy; ³Department of Medical Science and Biotechnology, University of Foggia, Foggia, Italy; ⁴UOS Clinica dei Pazienti del Territorio, Policlinico Gemelli, Rome, Italy; ⁵Faculty of Parasitology, Aristotle University of Thessaloniki, Macedonia, Greece; ⁶Department of Microbiology and Infectious Diseases, Aristotle University of Thessaloniki, Macedonia, Greece; ⁷Department of Pharmacology, University of Perugia, Perugia, Italy; and ⁸Cattolica University, Rome, Italy

ABSTRACT

Spores and fungal fragments found in indoor and outdoor environments originate from opportunistic fungi and they can contribute to inflammatory responses, causing a broad range of symptoms. Papers were selected and reviewed with an emphasis on the molecular mechanisms involved in the effect of fungi on immune cells, especially mast cells (MCs). Fungi can bind to antibodies and complement them, allowing them to be recognized by cells of the innate immune system, including macrophages, dendritic cells, and MCs, which are then stimulated via Toll-like receptor signaling. Fungi can cause diseases mediated by MCs and aggravate allergic inflammation. Immunosuppressed subjects can be particularly susceptible to developing diseases caused by opportunistic fungi. Mold also liberates mycotoxins that could be on volatile spores and stimulate MCs to secrete pro-inflammatory cytokines/chemokines, but this mechanism is not known. Fungi can activate the immune system directly or through mycotoxins, leading to stimulation of immune cells and chronic neuro-inflammatory symptoms. Some of these processes may be inhibited by the new anti-inflammatory cytokine interleukin 37. (*Clin Ther.* 2018;■:■■■-■■■) © 2018 Elsevier HS Journals, Inc. All rights reserved.

Key words: cytokines, fungi, innate immunity, infection, inflammation, macrophages, mast cells, mold, mycotoxins.

INTRODUCTION

Fungi are eukaryotic single-cell or multinucleate organisms that live by decomposing organic material. Molds are fungi growing in the form of multicellular filaments, called hyphae, on damp surfaces in soil, decaying vegetation, as well as in urban and rural settings.¹

Fungal exposure can lead to an increased risk of respiratory problems, such as asthma attacks, nasal and sinus congestion, eye irritation, sore throat, chronic cough, and sinusitis.²⁻⁵ *Aspergillus fumigatus* is one of the most common fungi that can cause severe pathology in immunocompromised hosts.^{6,7}

IMMUNE RESPONSES

Immunity to fungi⁸ involves activation of Toll-like receptors (TLRs) generating inflammatory cytokines through pattern-recognition receptors and pathogen-associated molecular patterns.^{9,10} In humans, TLRs range from TLR1 to TLR13 proteins, most of which are expressed on the cell membrane; in contrast, TLR3, TLR7, TLR8, TLR9, TLR11, TLR12, and TLR13 are expressed intracellularly on endoplasmic reticulum, endosomes, phagosomes, and lysosomes.¹¹ Apart from TLR3, all TLRs engage TIRAP, which

Accepted for publication April 18, 2018.

<https://doi.org/10.1016/j.clinthera.2018.04.010>

0149-2918/\$ - see front matter

© 2018 Elsevier HS Journals, Inc. All rights reserved.

leads to activation of MyD88 and the adaptor molecule IRAK complex.¹² The subsequent phosphorylation cascade engages IRAK4, TRAF6, and TAK, which activate both NF- κ B and MAPK, causing gene enhancement that regulates cell differentiation, proliferation, and inflammation.^{13,14}

Bacteria, fungi, viruses, and parasites share the capacity to induce a major production of interleukin (IL)-17 during the early innate immune response. T-helper (Th) 17 cells react with IL-1 receptor type 1 by activating the IL-6/STAT3 cascade and generating IL-17A, IL-17F, IL-21, and IL-22.¹⁵ In the innate response, fungal infections provoke the release of IL-17 with consequent inflammatory response.¹⁶ Such responses can be regulated by the cytokine IL-36, which shares the same co-receptor with IL-1, and can regulate Th17 responses,¹⁷ as well as *Aspergillus fumigatus*-induced Th1 and Th17 responses.¹⁸

CYTOKINES

Cytokines are a family of structurally and functionally related proteins that exhibit pleiotropic effects on the growth and function of a variety of cell types.^{19,20}


Cytokines orchestrate the host defense against mold by mediating acute and chronic inflammation.²¹

IL-1 family members²² are produced in response to fungal infections and promote an innate immune response.^{23,24} Fungi-induced allergy and asthma are characterized by stimulation of mast cells (MCs), which generate many inflammatory mediators.^{25–27} The allergic reactions to molds are characterized by high levels of IgE and increased numbers of MCs and eosinophils.^{28,29} In fact, MCs and dendritic cells communicate for optimal antigen transfer and T-cell activation.^{30,31} MCs can respond to many non-immune stimuli, including the cytokines IL-1 and IL-33.^{32,33}

MCs may play a major role in the defense against pathogens, but can also contribute to pathogen-associated neurodegenerative diseases.^{34,35}

IL-37 as Potential Inhibitor of Inflammation Induced by Fungi

IL-37, formerly IL-1F7, is a natural inhibitor of innate immunity by binding IL-18R α chain, improving inflammatory diseases.^{36–38} IL-37 directly inhibits MyD88, reducing the generation of inflammatory



IL-1 family members. IL-37 down-regulates macrophage cytokine release and, therefore, innate immunity.³⁹

We propose that, in addition to immunotherapy,⁴⁰ IL-37 may be a potentially useful treatment against fungi-induced inflammation (Figure). However, even though the therapeutic use of IL-37 in inflammatory diseases remains a promising approach, more studies are needed to clarify its side effects, clinical dosage, and efficacy in vivo.

ACKNOWLEDGMENTS

None.

CONFLICTS OF INTEREST

The authors have indicated that they have no conflicts of interest regarding the content of this article

REFERENCES

- Nair DN, Padmavathy S. Impact of endophytic micro-organisms on plants, environment and humans. *ScientificWorldJournal*. 2014;2014:250693.
- Park JH, Cox-Ganser JM. Mold exposure and respiratory health in damp indoor environments. *Front Biosci (Elite Ed)*. 2011;3:757-771.
- Vacher G, Niculita-Hirzel H, Roger T. Immune responses to airborne fungi and non-invasive airway diseases. *Semin Immunopathol*. 2015;37:83-96.
- (a). Knutsen AP, Bush RK, Demain JG, et al. Fungi and allergic lower respiratory tract diseases. *J Allergy Clin Immunol*. 2012;129:280-291. quiz 292-3.
(b). Ghosh S, Hoselton SA, Dorsam GP, Schuh JM. Eosinophils in fungus-associated allergic pulmonary disease. *Front Pharmacol*. 2013;4:8.
- Moloney NM, Owens RA, Doyle S. Proteomic analysis of *Aspergillus fumigatus* - clinical implications. *Expert Rev Proteomics*. 2013;13:635-649.
- Chrenkova V, Hubka V, Cetkovsky P, et al. Proven Invasive Pulmonary Aspergillosis in Stem Cell Transplant Recipient Due to *Aspergillus subulatus*, a Cryptic Species of *A. nidulans*. *Mycopathologia*. 2018;183:423-429.
- Blatzer M, Latgé JP. Metal-homeostasis in the pathobiology of the opportunistic human fungal pathogen *Aspergillus fumigatus*. *Curr Opin Microbiol*. 2017;40:152-159.
- LeibundGut-Landmann S, Wüthrich M, Hohl TM. Immunity to fungi. *Curr Opin Immunol*. 2012;24:449-458.
- Taghavi M, Khosravi A, Mortaz E, et al. Role of pathogen-associated molecular patterns (PAMPS) in immune responses to fungal infections. *Eur J Pharmacol*. 2017;808:8-13.
- Franzenburg S, Fraune S, Künzel S, et al. MyD88-deficient Hydra reveal an ancient function of TLR signaling in sensing bacterial colonizers. *Proc Natl Acad Sci U S A*. 2012;109:19374-19379.
- Plato A, Hardison SE, Brown GD. Pattern recognition receptors in antifungal immunity. *Semin Immunopathol*. 2015;37:97-106.
- Zuo L, Lucas K, Fortuna CA, et al. Molecular Regulation of Toll-like Receptors in Asthma and COPD. *Front Physiol*. 2015;6:312.
- Konno H, Yamamoto T, Yamazaki K, et al. TRAF6 establishes innate immune responses by activating NF-kappaB and IRF7 upon sensing cytosolic viral RNA and DNA. *PLoS ONE*. 2009;4:e5674.
- Pennini ME, Perkins DJ, Salazar AM, et al. Complete dependence on IRAK4 kinase activity in TLR2, but not TLR4, signaling pathways underlies decreased cytokine production and increased susceptibility to *Streptococcus pneumoniae* infection in IRAK4 kinase-inactive mice. *J Immunol*. 2013;190:307-316.
- Sha Y, Markovic-Plese S. A role of IL-1R1 signaling in the differentiation of Th17 cells and the development of autoimmune diseases. *Self Nonself*. 2011;2:35-42.
- Isailovic N, Daigo K, Mantovani A, Selmi C. Interleukin-17 and innate immunity in infections and chronic inflammation. *J Autoimmun*. 2015;60:1-11.
- Carrier Y, Ma HL, Ramon HE, et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. *J Invest Dermatol*. 2011;131:2428-2437.
- Gresnigt MS, Rösler B, Jacobs CW, et al. The IL-36 receptor pathway regulates *Aspergillus fumigatus*-induced Th1 and Th17 responses. *Eur J Immunol*. 2013;43:416-426.
- Ebrahimpour S, Shahbazi M, Khalili A, et al. Elevated levels of IL-2 and IL-21 produced by CD4+ T cells in inflammatory bowel disease. *J Biol Regul Homeost Agents*. 2017;31:279-287.
- Amaral RC, Barbeiro DF, Koike MK, et al. Cytokine and chemokine levels in the heart tissue of aged rats following severe acute pancreatitis. *Eur J Inflamm*. 2017;15:102-106.
- Marinari S, De Iuliis V, Dadorante V, et al. Cytokine modulation in patients with idiopathic pulmonary fibrosis undergoing treatment with steroids, immunosuppressants, and IFN-γ 1b. *J Biol Regul Homeost Agents*. 2017;31:59-69.
- Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. *Immunity*. 2013;39:1003-1018.
- Rivera-Mariani FE, Vysyaraju K, Negherbon J, et al. Comparison of the interleukin-1β-inducing potency of allergenic spores from higher fungi (basidiomycetes) in a cryopreserved human whole blood system. *Int Arch Allergy Immunol*. 2014;163:154-162.

24. Conti C, Caraffa A, Kritas SK, et al. Alexithymia and its relationships with inflammatory response mediated by IL-1 family members. *J Biol Regul Homeost Agents*. 2017;31: 21–28.
25. Galli SJ, Kalesnikoff J, Grimbaldston MA, et al. Mast cells as "tunable" effector and immunoregulatory cells: recent advances. *Annu Rev Immunol*. 2005;23:749–786.
26. Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis and related disorders. *New Engl J Med*. 2015;373:163–172.
27. Conti P, Caraffa A I, Kritas SK, et al. Mast cell, pro-inflammatory and anti-inflammatory: Jekyll and Hyde, the story continues. *J Biol Regul Homeost Agents*. 2017;31:263–267.
28. Lopes JP, Stylianou M, Nilsson G, Urban CF. Opportunistic pathogen *Candida albicans* elicits a temporal response in primary human mast cells. *Sci Rep*. 2015;5:12287.
29. Saluja R, Metz M, Maurer M. Role and relevance of mast cells in fungal infections. *Front Immunol*. 2012;3:146.
30. Carroll-Portillo A, Cannon JL, te Riet J, et al. Mast cells and dendritic cells form synapses that facilitate antigen transfer for T cell activation. *J Cell Biol*. 2015;210:851–864.
31. Galli SJ, Gaudenzio N. Human mast cells as antigen-presenting cells: When is this role important in vivo? *J Allergy Clin Immunol*. 2018;141:92–93.
32. Kandere-Grzybowska K, Letourneau R, Kempuraj D, et al. IL-1 induces vesicular secretion of IL-6 without degranulation from human mast cells. *J Immunol*. 2003;171: 4830–4836.
33. Taracanova A, Alevizos M, Karagkouni A, et al. SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. *Proc Natl Acad Sci U S A*. 2017;114: E4002–E4009.
34. Girolamo F, Coppola C, Ribatti D. Immunoregulatory effect of mast cells influenced by microbes in neurodegenerative diseases. *Brain Behav Immun*. 2017;65:68–89.
35. Quigley EMM. Microbiota-Brain-Gut Axis and Neurodegenerative Diseases. *Curr Neurol Neurosci Rep*. 2017;17:94.
36. Boraschi D, Lucchesi D, Hainzl S, et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. *Eur Cytokine Netw*. 2011;22:127–147.
37. Conti P, Carinci F, Lessiani G, et al. Potential therapeutic use of IL-37: a key suppressor of innate immunity and allergic immune responses mediated by mast cells. *Immunol Res*. 2017;65:982–986.
38. Carinci F, Lessiani G, Spinasi E, et al. Mast cell and cancer with special emphasis on IL-37 an anti-inflammatory and inhibitor of innate immunity: new frontiers. *J Biol Regul Homeost Agents*. 2016;30:945–950.
39. Zhan Q, Zeng Q, Song R, et al. IL-37 suppresses MyD88-mediated inflammatory responses in human aortic valve interstitial cells. *Mol Med*. 2017;23.
40. Ravikumar S, Win MS, Chai LY. Optimizing outcomes in immunocompromised hosts: understanding the role of immunotherapy in invasive fungal diseases. *Front Microbiol*. 2015;6:1322.

Address correspondence to: Pio Conti, PhD, Immunology Division, Postgraduate Medical School, University of Chieti-Pescara, Chieti, Italy. E-mail: pconti@unich.it